Evidence map›Paper›PMID 39263365›Full record

ArticleFuture healthcare journal2024

Real-world learnings for digital health industry

Rebecca Pope, Alexandros Zenonos, William Bryant, Anastasia Spiridou, Daniel Key, Shiren Patel, Jack Robinson, Anna Styles, Chris Rockenbach, Gina Bicknell and 3 more

Abstract read
In one paragraph

Article in Future healthcare journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Artificial intelligence: friend or foe?Future healthcare journal · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rebecca PopeRoche Products Limited, United Kingdom.
Alexandros ZenonosRoche Products Limited, United Kingdom.
William BryantGreat Ormond Street Hospital for Children NHS Foundation Trust and NIHR GOSH Biomedical Research Centre, United Kingdom.
Anastasia SpiridouGreat Ormond Street Hospital for Children NHS Foundation Trust and NIHR GOSH Biomedical Research Centre, United Kingdom.
Daniel KeyGreat Ormond Street Hospital for Children NHS Foundation Trust and NIHR GOSH Biomedical Research Centre, United Kingdom.
Shiren PatelGreat Ormond Street Hospital for Children NHS Foundation Trust and NIHR GOSH Biomedical Research Centre, United Kingdom.
Jack RobinsonRoche Products Limited, United Kingdom.
Anna StylesRoche Products Limited, United Kingdom.
Chris RockenbachGreat Ormond Street Hospital for Children NHS Foundation Trust and NIHR GOSH Biomedical Research Centre, United Kingdom.
Gina BicknellPinsent Masons LLP, United Kingdom.
Pavithra RajendranGreat Ormond Street Hospital for Children NHS Foundation Trust and NIHR GOSH Biomedical Research Centre, United Kingdom.
Andrew M TaylorGreat Ormond Street Hospital for Children NHS Foundation Trust and NIHR GOSH Biomedical Research Centre, United Kingdom.
Neil J SebireGreat Ormond Street Hospital for Children NHS Foundation Trust and NIHR GOSH Biomedical Research Centre, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several publications have indicated potential benefit from collaboration with industry regarding wider use of anonymised routine NHS healthcare data. However, there is limited guidance regarding exactly how such collaborations between NHS hospitals and industry partners should best be carried out, and specific issues that need to be addressed at an individual project or collaboration level to achieve desired benefit. Specifically, routine health data are complex, not collected in a format optimised for secondary use, and often require interpretation based on clinical understanding of the medical conditions or patients. In order to address these issues, a formal partnership collaboration was established between an NHS organisation (Great Ormond Street Hospital for Children) and a pharmaceutical company (Roche Products Limited), to jointly understand the problems that require solving in order to maximise such use of NHS data to support improved patient outcomes and other patient/NHS benefit in a more sustainable way. We present the learnings from the first 2 years of the 5-year collaboration addressing aspects such as complexities of NHS Electronic Patient Record (EPR), data engineering and use of modern technology to optimise such data. Plus, the development of appropriate technology and data infrastructure within the NHS to support interoperability and prepare the NHS for wider application of artificial intelligence. We also highlight the staff skills and training needed to support such systems in the NHS, governance structures and processes needed to ensure appropriate use of tools and data and how best to co-design with patients, their families, and clinical teams. It is hoped that this review may provide useful information for both healthcare organisations and industry partners working towards the future of optimal use of data and technology for healthcare benefit.

Indexed as

CollaborationInformaticsInformation technologyLife sciences industry strategyPartnership

Identifiers

PMID39263365
PMCPMC11387268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.